Jazz Pharmaceuticals plc
Jazz Pharmaceuticals develops and commercializes pharmaceutical products for unmet medical needs. Products include Xywav, Xyrem, Epidiolex, Zepzelca, Rylaze, Enrylaze, Defitelio, and Vyxeos. The company also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma. Jazz Pharmaceuticals has agreements with XL-protein GmbH, Redx Pharma plc, and Autifony Therapeutics Limited for preclinical activities. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.
Overview
Strengths
- Creates economic value: ROIC of 14.0% against a cost of capital (WACC) of 4.8%, a spread of 9.2 percentage points.
- High-quality earnings: over the last 6 years, free cash flow added up to 1,834% of reported net income.
- Valued below its Biotechnology peers: P/FCF 12.2x vs. a median of 20.2x.
- Consistent growth: revenue has compounded at 12.5% a year over 5 years, rising every year.
- Paying down debt: long-term debt fell by 13.5 percentage points of total assets last year.
Weaknesses
- Operating profit does not cover interest expense.
- Our discounted cash flow model finds no value to support the current price: operating profit does not cover interest expense.
- Currently loss-making: the latest fiscal year closed with a net loss.
- High leverage: net debt is 3.3x EBITDA, against a median of 0.5x for its Biotechnology peers.
- Earnings are projected to decline (-10.0% per year).
Key Financial Data